Meeting
2022 ASCO Annual Meeting
Adverse health outcomes (AHO) in testis cancer survivors (TCS) following high-dose chemotherapy (HDCT) and autologous stem cell transplant.
Authors
Meagan Elizabeth Miller
Indiana University School of Medicine, Indianapolis, IN
Meagan Elizabeth Miller , Ryan Ashkar , Sandra K. Althouse , Nasser H. Hanna , Rafat Abonour , Lois B. Travis , Lawrence H. Einhorn , Nabil Adra , Mohammad Issam Abu Zaid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12083)
DOI
10.1200/JCO.2022.40.16_suppl.12083
Abstract #
12083
Poster Bd #
329
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.
First Author: Andreas Georg Wibmer
Poster
2020 ASCO Virtual Scientific Program
Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.
First Author: Eoghan Ruadh Malone
Poster
2016 ASCO Annual Meeting
Estimation of 10-year (y) cardiovascular disease (CVD) risk after cisplatin-based chemotherapy (CBCT): A multi-institutional study of 459 germ cell tumor (GCT) survivors in the Platinum study.
First Author: Darren R. Feldman
Poster
2015 ASCO Annual Meeting
Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian Testicular Cancer Survivors (TCS).
First Author: Heather E. Wheeler